These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 5014505)

  • 21. Nucleic acids. 16. Orally active derivatives of ara-cytidine.
    Wechter WJ; Gish DT; Greig ME; Gray GD; Moxley TE; Kuentzel SL; Gray LG; Gibbons AJ; Griffin RL; Neil GL
    J Med Chem; 1976 Aug; 19(8):1013-7. PubMed ID: 966247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1-beta-D-arabinofuranosylcytosine (Cytarabine).
    Bach MK
    Cancer Res; 1969 May; 29(5):1036-44. PubMed ID: 5781095
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiviral activity of O'-alkylated derivatives of cytosine arabinoside.
    De Clercq E; Darzynkiewicz E; Shugar D
    Biochem Pharmacol; 1975 Feb; 24(4):523-7. PubMed ID: 1111551
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
    Van Maarseveen JH; Hermkens PH; De Clercq E; Balzarini J; Scheeren HW; Kruse CG
    J Med Chem; 1992 Aug; 35(17):3223-30. PubMed ID: 1324318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppressive effects of adamantoyl cytarabine. I. Inhibition of hemagglutinin formation and graft versus host reactions in mice.
    Gray GD; Mickelson MM; Crim JA
    Biochem Pharmacol; 1969 Sep; 18(9):2163-9. PubMed ID: 4390558
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of activity of herpes virus inhibitors.
    Collins P; Bauer DJ
    J Antimicrob Chemother; 1977 Mar; 3 Suppl A():73-81. PubMed ID: 405365
    [No Abstract]   [Full Text] [Related]  

  • 27. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.
    Schrecker AW; Goldin A
    Cancer Res; 1968 Apr; 28(4):802-3. PubMed ID: 5649067
    [No Abstract]   [Full Text] [Related]  

  • 28. Suppression of immunity by phenobarbital.
    Park SK; Brody JI
    Nat New Biol; 1971 Oct; 233(40):181-2. PubMed ID: 5287088
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin.
    Gallo RC; Whang-Peng J; Adamson RH
    J Natl Cancer Inst; 1971 Apr; 46(4):789-95. PubMed ID: 4995657
    [No Abstract]   [Full Text] [Related]  

  • 30. Letter: Proposed new derivative of cytosine arabinoside (NSC-63878) to circumvent resistance.
    Cysyk RL
    Cancer Chemother Rep; 1974; 58(3):298-9. PubMed ID: 4842665
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
    Mizuno NS; Humphrey EW
    Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacodynamic and pharmacokinetic measurements of antitumor agents.
    Mellett LB
    Clin Pharmacol Ther; 1974 Jul; 16(1):230-42. PubMed ID: 4210526
    [No Abstract]   [Full Text] [Related]  

  • 33. The mechanisms of action of three fluorine substituted cytosine analogs: implications for cancer chemotherapy.
    Tattersall MH; Ganeshaguru K; Hoffbrand AV
    Biochem Pharmacol; 1974 Sep; 23(18):2533-6. PubMed ID: 4416357
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel arabinofuranosyl derivatives of cytosine resistant to enzymatic deamination and possessing potent antitumor activity.
    Bobek M; Cheng YC; Bloch A
    J Med Chem; 1978 Jul; 21(7):597-8. PubMed ID: 276611
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of phosphorylated cyclocytidine on deoxyribonucleic acid polymerase.
    Hoshi A; Kanzawa F; Kuretani K; Kanai T; Ichino M
    Biochem Pharmacol; 1973 Nov; 22(22):2829-34. PubMed ID: 4761553
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 37. Tentative mechanism of lymphocyte chalone action.
    Attallah AM; Houck JC
    Exp Cell Res; 1977 Mar; 105(1):137-41. PubMed ID: 190025
    [No Abstract]   [Full Text] [Related]  

  • 38. Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: pharmacology.
    Oliverio VT
    Cancer Chemother Rep 3; 1972 May; 3(1):69-71. PubMed ID: 4114997
    [No Abstract]   [Full Text] [Related]  

  • 39. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.
    Skipper HE; Schabel FM; Wilcox WS
    Cancer Chemother Rep; 1967 Jun; 51(3):125-65. PubMed ID: 6043735
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunochemotherapy of human cancer.
    Gutterman JU; Mavligit GM; Reed RC; Hersh EM
    Semin Oncol; 1974 Dec; 1(4):409-23. PubMed ID: 4620443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.